Immune infiltration in aggressive papillary craniopharyngioma: High infiltration but low action

Yanfei Jia, Lin Ma, Kefan Cai, Bochao Zhang, Wentao Wu, Youchao Xiao, Ning Qiao, Siming Ru, Lei Cao, Hua Gao, Songbai GuiFrontiers in Immunology 2022 · DOI

TL;DR

This study reveals that aggressive papillary craniopharyngiomas (PCPs) exist in a paradoxical state of "high infiltration but low action"—they are packed with immune cells that remain largely inactive. The researchers identified that high levels of neutrophils likely suppress the immune response, and they developed a highly accurate predictive model using inflammatory markers IL1A and IL6 to determine the degree of tumor invasion into the hypothalamus.

What Problem Does This Paper Address?

Papillary craniopharyngiomas (PCPs) are rare brain tumors that are histologically "benign" (non-cancerous) but clinically devastating. Their location near the hypothalamus means that as they grow and invade surrounding tissue, they cause severe complications like morbid obesity, endocrine failure, and vision loss.

While the immune landscape of the more common subtype (adamantinomatous craniopharyngioma, or ACP) has been studied, the immune microenvironment (IME) of PCPs remained a "black box." Surgeons often observe signs of intense inflammation during operations—such as yellow fibrin and tissue edema—but the underlying molecular mechanisms driving this aggression and the specific role of immune cells were unknown. This paper seeks to bridge that gap to find better ways to predict and potentially treat tumor invasiveness.

Methods

The authors employed a multi-omic approach to dissect the PCP microenvironment:

  • Transcriptomics: They performed bulk-RNA sequencing on 11 PCP samples and 5 normal brain tissues.
  • Immune Profiling: Using the ssGSEA (single-sample Gene Set Enrichment Analysis) and the ESTIMATE algorithm, they quantified the infiltration of 28 different immune cell subtypes.
  • Validation: Findings were validated using qRT-PCR (on an additional 36 samples) and Immunohistochemistry (IHC) to visualize protein expression in tissue sections.
  • Predictive Modeling: The team used LASSO (Least Absolute Shrinkage and Selection Operator) regression to build a diagnostic model. This model uses the expression levels of IL1A and IL6 to predict "Puget grade 2" invasion (the most aggressive form of hypothalamic involvement).
  • Pathway Analysis: GO (Gene Ontology) and KEGG enrichment analyses were used to identify the biological processes (like odontogenesis and inflammatory signaling) associated with the most aggressive tumors.

Datasets

The study utilized several small but targeted cohorts:

  • Discovery Cohort: 11 human PCP tumor samples and 5 normal brain tissues (from trauma patients) for bulk-RNA sequencing.
  • Validation Cohort: 36 additional PCP tumor samples categorized by the Puget grading system (Grade 0: low aggression; Grade 2: high aggression) for qRT-PCR and IHC analysis.
  • Public Benchmarks: The researchers used standard reference genomes (hg38) and established immune cell gene signatures for their bioinformatic pipelines.

Key Insights and Ideas

  • The Paradox of "Lazy" Immunity: PCPs show significantly higher infiltration of almost all immune cell types compared to normal brain tissue. However, despite this "crowd," the tumors remain aggressive, suggesting the immune cells are being actively suppressed rather than attacking the tumor.
  • Neutrophils as the "Killjoys": The data showed a strong negative correlation between neutrophil infiltration and the presence of effector T cells (the "soldiers" of the immune system). The authors hypothesize that neutrophils in the PCP microenvironment act similarly to Myeloid-Derived Suppressor Cells (MDSCs), creating a shield that prevents an effective anti-tumor response.
  • Inflammation Drives Invasion: Aggressive tumors (Puget Grade 2) showed much higher expression of inflammatory mediators IL1A and IL6. These aren't just markers; they appear to be linked to the physical "brittleness" and edema that make these tumors so difficult to remove surgically.
  • Molecular Mimicry: Enrichment analysis suggested that aggressive PCPs reactivate pathways related to odontogenesis (tooth formation), a curious biological overlap often seen in craniopharyngiomas due to their embryonic origins.

Key Results

  • High Diagnostic Accuracy: The IL1A and IL6-based LASSO model was remarkably effective at distinguishing between low-invasion and high-invasion tumors, achieving an AUC (Area Under the Curve) of 0.89 in the training set and 0.96 in the testing set.
  • Immune Scoring: Aggressive (Grade 2) tumors had significantly higher overall immune scores (p = 0.0402) and higher specific counts of macrophages, MDSCs, and regulatory T cells compared to Grade 0 tumors.
  • Checkpoint Expression: IHC staining confirmed high levels of PD-1 and PD-L1 in aggressive tissues, further explaining why the dense immune infiltration fails to act against the tumor.

Limitations and Future Work

The primary limitation is the small sample size (n=11 for sequencing), which is common in studies of rare pathologies but can introduce bias. Additionally, because the study used bulk-RNA sequencing, the researchers could not see exactly where the immune cells were located relative to the tumor cells or how they were interacting on a cell-to-cell basis.

The authors suggest that future research should utilize single-cell RNA sequencing (scRNA-seq) to provide a higher-resolution map of these interactions. Clinically, this work opens the door for testing IL1A and IL6 inhibitors as potential therapies to reduce tumor inflammation and prevent invasion into the hypothalamus, potentially making surgeries safer and more effective.

Summary updated

Abstract

Papillary craniopharyngiomas (PCPs) are biologically benign but clinically aggressive lesions hence affect the quality of life. The expression of inflammatory mediators and regulation of the immune microenvironment in PCPs have not been investigated much. In this study, for the first time, we assessed the immune cell infiltration and immune cell signatures in PCPs by analyzing the bulk-RNA sequencing data and immunohistochemical staining. Additionally, we performed qRT-PCR analysis to detect inflammatory mediators interleukin-1α (<i>IL1A</i>) and interleukin-6 (<i>IL6</i>) in different aggressive groups and then developed the <i>IL1A</i> and <i>IL6</i> prediction models for defining the degree of hypothalamic invasion. Lastly, we defined differentially expressed genes related to invasiveness and implemented enrichment analysis to them. Our results indicated that PCPs are in a state of high immune infiltration but low action with abundant inflammatory cells. High infiltration of neutrophils may lead a low active immune microenvironment. Furthermore, the high expression level of <i>IL1A</i> and <i>IL6</i> was positively correlated with the invasion of PCP tumors in the hypothalamus. These findings provide new pathological insights into the underlying mechanism of the immune microenvironment in PCP tumors. Moreover, <i>IL1A</i> and <i>IL6</i> might serve as potential therapeutic targets for PCP tumors, especially to prevent their invasion into the hypothalamus.
BibTeX
@inproceedings{jia2022immune,
  author = {Yanfei Jia and Lin Ma and Kefan Cai and Bochao Zhang and Wentao Wu and Youchao Xiao and Ning Qiao and Siming Ru and Lei Cao and Hua Gao and Songbai Gui},
  title = {{Immune infiltration in aggressive papillary craniopharyngioma: High infiltration but low action}},
  booktitle = {Frontiers in Immunology},
  year = {2022},
  doi = {10.3389/fimmu.2022.995655},
}
Figure